Can Phase III Trials indicate shifts in M&A interest?

15/09/2026

At Sunstone, we invest in early-stage therapeutics with the aim of developing future and clinically relevant drug candidates for partnering with, or acquisition by, the pharmaceutical industry. The challenge is to triangulate potential patient benefit and development...

Europe’s biotech ecosystem is broken at the ends

07/07/2026

Europe’s biotech ecosystem is broken at the ends The middle holds. The ends are collapsing. Fresh startups and near-commercial firms are strained and cannot access capital in EU. Without more qualified early-stage funding now, there will be no mature EU biotech...

MinvervaX CFO & CDO Appointment

19/04/2026

MinvervaX CFO & CDO Appointment MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announces the appointments of Jamila Louahed as Chief Development Officer and Hans...

Is biotech venture capital investing more to return less?

12/02/2026

At Sunstone we continue to track risk-adjusted return multiples (adjusted for contingent payments) versus the total capital invested in private therapeutic companies prior to M&A exits. When looking at the median trends over the past 15 years, the inflection...